1. To consider and approve the Audited Financial Results of the Company for the Financial Year ended 31st March, 2025. 2. To take on record the resignation of CS Avneet Kaur (ACS - 27857) ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.8 pts more than Nifty Microcap 250 and 2.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The board approved the audited financial results for FY ending 31 March 2025. Revenue grew to Rs. 97.52 crore from Rs. 80.19 crore (~21.6% growth), while profit after tax rose to Rs. 5.35 crore from Rs. 4.07 crore (~31.5% growth). EPS stood at Rs. 6.94 versus Rs. 5.36 last year, and no dividend was proposed. The board accepted the resignation of Ms. Avneet Kaur as Company Secretary and Compliance Officer (a Key Managerial Personnel), effective 5 June 2025. The company also terminated its agreement with KFin Technologies as Registrar and Share Transfer Agent and appointed Beetal Financial & Computer Services as the new RTA. Internal and Secretarial Auditors for FY26 were approved, along with related party transactions of up to Rs. 89 crore with group entities including Astonea One, Ascot Biolabs, and Shinto Organics.
Healthy top-line and bottom-line growth for FY25 is positive for shareholders, though the resignation of the company secretary and the change of RTA are routine governance items. No dividend was declared despite improved profits, which may disappoint income-focused investors.